MEDICINES360
Creating Equitable Access
MEDICINES360
EIN: 26-4443340
Mission
Medicines360 is a non-profit pharmaceutical organization working toward a world where all women have access to the medicines they need. Our mission is to catalyze equitable access to medicines & devices through product development, policy advocacy, and collaboration with U.S. and global partners.
Ruling year
2009
Principal Officer
Tina Raine-Bennett, MD, MPH
Main address
49 Stevenson Street Suite 1100
San Francisco, CA 94105 USA
EIN
26-4443340
Philanthropy and public policy
Health care access
Reproductive health care
Pharmacology
Diseases and conditions
Population served
Women and girls
NTEE code
(Research Institutes and/or Public Policy Analysis) (G05)
IRS subsection
501(c)(3) Public Charity
IRS filing requirement
This organization is required to file an IRS Form 990 or 990-EZ.
Tax forms
Communication
Programs and results
What we aim to solve
We believe the nonprofit pharma model can help speed the transformation of the healthcare system to ensure equitable access to life-altering medicines. Unbeholden to shareholder interests, our model is catalyzing increased access to affordable medicines that address unmet medical needs for women’s health.
Our programs
What are the organization's current programs, how do they measure success, and who do the programs serve?
Conducting pharmaceutical development to bring new medicines to market
Founded in 2009 because the most effective forms of reversible contraception were too expensive and out of reach, Medicines360 is a nonprofit pharmaceutical organization that prioritizes women over profit to ensure equitable access to medicines.
Today, our focus is to develop and provide a broader range of high-quality products that will help fill gaps in women’s health. Our experience in drug development, clinical trial research, and regulatory affairs makes us uniquely positioned to address the high cost of medicines in the U.S and globally.
Medicines360 has products called LILETTA® and AVIBELA™ that are available in many countries and regions, but not all.
Identifying gaps through research and analysis
Continually assess the market to identify barriers women face in accessing the health products they need.
Engaging in values-aligned collaborations that further our mission
Forming key relationships with nonprofits, pharmaceutical companies, and global non-governmental organizations (NGOs) who are critical to helping develop, distribute, and market medicines in the US and globally.
Where we work
External reviews
Our results
How does this organization measure their results? It's a hard question but an important one.
Number of products distributed
This metric is no longer tracked.Totals By Year
Related Program
Conducting pharmaceutical development to bring new medicines to market
Type of Metric
Output - describing our activities and reach
Direction of Success
Holding steady
Context Notes
To date, in collaboration with our commercial partner, we have made our hormonal IUD available to more than 1.2 million women throughout the United States.
Our Sustainable Development Goals
Learn more about Sustainable Development Goals.
Goals & Strategy
Learn about the organization's key goals, strategies, capabilities, and progress.
Charting impact
Four powerful questions that require reflection about what really matters - results.
What is the organization aiming to accomplish?
Since our founding in 2009, we have learned critical lessons that have informed our priorities for the next chapter in our pursuit of equitable access. Complex problems require multi-faceted, long-term solutions. As a social enterprise, we are driven to help make equitable access to medicines a reality for women. Our organization has developed momentum to address one of the most pressing issues that plague our current system – the high cost of drugs that prohibits access for many women. We will continue engaging with stakeholders and philanthropic donors to bring new and expanded resources to our work in product development, policy advocacy, and public sector engagement.
What are the organization's key strategies for making this happen?
Key Priorities:
1. Grow Our Impact: Expand the portfolio of women's health products that increase access and/or healthcare choice
2. Deliver on Medicines360's Promise: Expand AVIBELA's global impact
3. Capitalize on Our Success: Maximize our impact and act as a catalyst for change
4. Create Points of Leverage In the Community: Develop strategic relationships to acquire pipeline products and capital for R&D
What are the organization's capabilities for doing this?
What have they accomplished so far and what's next?
How we listen
Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.
-
How is your organization using feedback from the people you serve?
-
Which of the following feedback practices does your organization routinely carry out?
-
What challenges does the organization face when collecting feedback?
Financials
Financial documents
Download audited financialsRevenue vs. expenses: breakdown
Liquidity in 2021 info
18.61
Months of cash in 2021 info
1.9
Fringe rate in 2021 info
16%
Funding sources info
Assets & liabilities info
MEDICINES360
Revenue & expensesFiscal Year: Jan 01 - Dec 31
SOURCE: IRS Form 990
MEDICINES360
Balance sheetFiscal Year: Jan 01 - Dec 31
SOURCE: IRS Form 990
The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.
Fiscal Year: Jan 01 - Dec 31
SOURCE: IRS Form 990
This snapshot of MEDICINES360’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.
Created in partnership with
Business model indicators
| Profitability info | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Unrestricted surplus (deficit) before depreciation | $9,067,234 | -$8,543,831 | $27,912,004 | -$5,230,488 | -$6,155,270 |
| As % of expenses | 54.5% | -40.5% | 118.4% | -22.8% | -27.6% |
| Unrestricted surplus (deficit) after depreciation | $8,668,097 | -$8,788,818 | $27,670,910 | -$5,577,826 | -$6,442,323 |
| As % of expenses | 50.9% | -41.2% | 116.2% | -23.9% | -28.5% |
| Revenue composition info | |||||
|---|---|---|---|---|---|
| Total revenue (unrestricted & restricted) | $23,326,051 | $16,684,261 | $17,400,453 | $12,024,199 | $24,675,342 |
| Total revenue, % change over prior year | 204.0% | -28.5% | 4.3% | -30.9% | 105.2% |
| Program services revenue | 44.1% | 52.7% | 0.0% | 0.0% | 0.0% |
| Membership dues | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Investment income | 9.2% | 13.2% | 12.8% | 13.7% | 4.3% |
| Government grants | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| All other grants and contributions | 31.4% | 3.6% | 45.9% | 4.0% | 0.1% |
| Other revenue | 15.3% | 30.5% | 41.3% | 82.3% | 95.5% |
| Expense composition info | |||||
|---|---|---|---|---|---|
| Total expenses before depreciation | $16,635,102 | $21,111,005 | $23,572,193 | $22,990,219 | $22,301,887 |
| Total expenses, % change over prior year | 2.6% | 26.9% | 11.7% | -2.5% | -3.0% |
| Personnel | 41.3% | 37.0% | 37.7% | 43.5% | 47.2% |
| Professional fees | 36.0% | 39.2% | 36.0% | 36.3% | 34.7% |
| Occupancy | 2.7% | 2.3% | 2.0% | 2.3% | 2.4% |
| Interest | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Pass-through | 0.3% | 0.1% | 0.1% | 0.0% | 0.0% |
| All other expenses | 19.7% | 21.4% | 24.2% | 17.8% | 15.7% |
| Full cost components (estimated) info | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total expenses (after depreciation) | $17,034,239 | $21,355,992 | $23,813,287 | $23,337,557 | $22,588,940 |
| One month of savings | $1,386,259 | $1,759,250 | $1,964,349 | $1,915,852 | $1,858,491 |
| Debt principal payment | $0 | $0 | $0 | $0 | $0 |
| Fixed asset additions | $0 | $0 | $590,484 | $0 | $327,162 |
| Total full costs (estimated) | $18,420,498 | $23,115,242 | $26,368,120 | $25,253,409 | $24,774,593 |
Capital structure indicators
| Liquidity info | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Months of cash | 4.2 | 2.4 | 1.4 | 0.9 | 1.9 |
| Months of cash and investments | 65.1 | 46.2 | 43.3 | 40.9 | 38.6 |
| Months of estimated liquid unrestricted net assets | 47.9 | 32.9 | 43.4 | 41.7 | 39.5 |
| Balance sheet composition info | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Cash | $5,852,048 | $4,144,895 | $2,804,283 | $1,710,899 | $3,494,867 |
| Investments | $84,338,539 | $77,090,983 | $82,295,121 | $76,665,039 | $68,172,800 |
| Receivables | $6,181,250 | $3,666,563 | $2,391,655 | $3,257,831 | $3,289,739 |
| Gross land, buildings, equipment (LBE) | $2,256,648 | $2,243,424 | $2,840,855 | $2,836,767 | $2,281,555 |
| Accumulated depreciation (as a % of LBE) | 61.0% | 73.0% | 66.4% | 78.3% | 71.3% |
| Liabilities (as a % of assets) | 30.4% | 32.3% | 3.9% | 4.5% | 5.1% |
| Unrestricted net assets | $67,250,867 | $58,462,049 | $86,132,959 | $80,555,133 | $74,112,810 |
| Temporarily restricted net assets | $1,314,481 | $500,940 | N/A | N/A | N/A |
| Permanently restricted net assets | $0 | $0 | N/A | N/A | N/A |
| Total restricted net assets | $1,314,481 | $500,940 | $0 | $0 | $0 |
| Total net assets | $68,565,348 | $58,962,989 | $86,132,959 | $80,555,133 | $74,112,810 |
Key data checks
| Key data checks info | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Material data errors | No | No | No | No | No |
Operations
The people, governance practices, and partners that make the organization tick.
Documents
Principal Officer
Tina Raine-Bennett, MD, MPH
Tina Raine-Bennett, MD, MPH, FACOG is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California (KPNC) Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship.
She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.
Number of employees
Source: IRS Form 990
MEDICINES360
Officers, directors, trustees, and key employeesSOURCE: IRS Form 990
Compensation data
MEDICINES360
Highest paid employeesSOURCE: IRS Form 990
Compensation data
MEDICINES360
Board of directorsas of 04/03/2023
Board of directors data
Leslie Benet, PhD
Ann Barber
Karen Dawes
Mike Dorsey
Lisa David
Board leadership practices
GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.
-
Board orientation and education
Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? No -
CEO oversight
Has the board conducted a formal, written assessment of the chief executive within the past year ? No -
Ethics and transparency
Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? No -
Board composition
Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? No -
Board performance
Has the board conducted a formal, written self-assessment of its performance within the past three years? No
Organizational demographics
Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.
Leadership
The organization's leader identifies as:
Race & ethnicity
No data
Gender identity
Sexual orientation
No data
Disability
No data
Equity strategies
Last updated: 03/30/2023GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more
- We review compensation data across the organization (and by staff levels) to identify disparities by race.
- We employ non-traditional ways of gathering feedback on programs and trainings, which may include interviews, roundtables, and external reviews with/by community stakeholders.
- We have long-term strategic plans and measurable goals for creating a culture such that one’s race identity has no influence on how they fare within the organization.
Contractors
Fiscal year endingProfessional fundraisers
Fiscal year endingSOURCE: IRS Form 990 Schedule G
Solicitation activities
GuideStar Pro Reports
Report successfully added to your cart!
Want more data?
A GuideStar Pro report containing the following information is available for this organization:
- Email contact information
- Financial trends metrics for five most recent years 2021, 2020, 2019, 2018, 2017*
- Financial statements for 2021
- Officer and/or Employee data for 2021, 2020, 2019, 2018, 2017
- Contractor and/or Paid Preparer data for 2021, 2020, 2019
- Board of Directors data for 2023
- *with the ability to download the data for 2021, 2020, 2019, 2018, 2017
Download it now for $125.
Need the ability to download nonprofit data and more advanced search options?Consider a Pro Search subscription.